Macular Degeneration
Conditions
Brief summary
This is a study in adults with geographic atrophy, an advanced form of age-related macular degeneration. The purpose of this study is to find out how well different doses of BI 754132 are tolerated. The participants are in the study for about 4 months. During this time, they visit the study site about 10 times. Participants receive 1 injection of BI 754132 directly into one of the eyes affected by geographic atrophy. In this study, BI 754132 is given to humans for the first time. The doctors compare how well participants tolerate the different doses of BI 754132. The doctors also regularly check the general health of the participants.
Interventions
DRUGBI 754132
One single injection
Sponsors
Boehringer Ingelheim
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- Men and women with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD): For the SRD part, the GA lesion in the study eye must be ≥ 1.9 mm2 disc area in size (approximately ≥ 0.75 disc area in size); For the MD part the total GA lesion size in the study eye must be ≥ 7.5 mm2 (approximately ≥ 3 disc area in size) * Fellow eye is not required to have GA * Best Corrected Visual Acuity (BCVA): * SRD part: BCVA of 20/100 to 20/400 Snellen (corresponding to 19 to 53 letters in the ETDRS chart) in the study eye equivalent measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol * MD part: BCVA score of ≤53 letters (Snellen equivalent of 20/100) in the study eye * Age ≥ than 50 years * Best-corrected VA in the non-study eye must have a better best-corrected VA compared to the study-eye * Women of childbearing potential (WOCBP) cannot be included. Men able to father a child must be ready and able to use highly effective methods of birth control per International Council on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information. * Signed informed consent consistent with International Council on Harmonisation Good Clinical Practice (ICH GCP) guidelines and local legislation prior to participation in the trial, which includes medication washout and restrictions * Not under any administrative or legal supervision or under institutionalization due to regulatory or juridical order
Exclusion criteria
* GA in either eye because of causes other than AMD * History of choroidal neovascularization (CNV) in the study eye and in the fellow eye * Previous treatment in the study eye for GA secondary to AMD within 6 months prior to screening visit (ongoing therapy with vitamin and mineral supplements is allowed) * Additional eye disease in the study eye that could compromise * best corrected VA (BCVA) with visual field loss, * uncontrolled glaucoma intraocular pressure (IOP\>24), * clinically significant diabetic maculopathy, * history of ischemic optic neuropathy or retinal vascular occlusion, * symptomatic vitreomacular traction, * genetic disorders such as retinitis pigmentosa); * history of high myopia \> 8 diopters in the study eye and * anterior segment and vitreous abnormalities in the study eye that would preclude adequate observation with Spectral Domain Optical Coherence Tomography (SD-OCT) * Any prior intraocular surgery in the study eye other then uneventful lens replacement for cataract within 3 months prior to screening * Aphakia or total absence of the posterior capsule. Yttrium aluminum garnet (YAG) laser capsulotomy permitted, more than 3 month prior to enrollment in the study eye * Current or planned use of medications known to be toxic to the retina, lens or optic nerve (e.g. desferoximine, chloroquine/hydrochloroquine, chlorpromazine, phenothiazines, tamoxifen, nicotinic acid, and ethambutol) * Significant disease or other medical conditions (as determined by medical history, examination and clinical investigations at screening) that may, in the opinion of the investigator result in the any of the following: * Put the patient at risk because of participation in the study * Influence the results of the study, * Cause concern regarding the patient's ability to participate in the study, e.g. cardiac (including tachycardia), gastro-intestinal, hepatic, renal, metabolic, dermatologic, neurological, haematological, oncological and psychiatric. * Patients with malignancy for which the patient has undergone resection, radiation or chemotherapy within past 5 years. Patients with treated basal cell carcinoma or fully cured squamous cell carcinoma are allowed. * Known hypersensitivity to any of the ingredients used in the Investigational Medical Product (IMP) formulation, or any of the medications used * Active intraocular inflammation in the study eye * Active infectious conjunctivitis in either eye * Further
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SRD Part: Number of Patients With Ocular (in the Study Eye) or Systemic Dose Limiting Events (DLEs) | From drug administration until end of trial, up to 100 days. | SRD part: Number of patients with ocular or systemic DLEs from drug administration. Systemic DLEs were defined as drug-related adverse events (AEs), as defined by the investigator, of moderate or severe intensity on the Common terminology criteria for adverse events (CTCAE) scale, and included diarrhea, cough, or patient-reported paraesthesia, dysgeusia, taste abnormality, taste disorder, or hyposmia. Single rising dose (SRD) part. |
| MD Part: Number of Patients With Drug Related Adverse Events (AEs) | From drug administration until end of trial, up to 155 days | Number of patients with drug-related adverse events (AEs). Multiple dose (MD) part. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SRD Part: Number of Patients With Any Ocular Adverse Events (AEs) in the Study Eye | From drug administration until end of trial, up to 100 days. | Number of patients with any ocular adverse events in the study eye. Single rising dose (SRD) part. |
| SRD Part: Area Under the Concentration-time Curve of BI 754132 in Serum Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | At Day 1, 4, 8, 15, 29, 56, 84 and Day 100. | Area under the concentration-time curve of BI 754132 in serum over the time interval from 0 extrapolated to infinity (AUC0-∞). Singe rising dose (SRD) part. |
| SRD Part: Time From Dosing to Maximum Serum Concentration of BI 754132 (Tmax) | At Day 1, 4, 8, 15, 29, 56, 84 and Day 100. | Time from dosing to maximum serum concentration of BI 754132 (tmax). Single rising dose (SRD part). |
| SRD Part: Maximum Serum Concentration of BI 754132 After a Single Intravitreal Dose (Cmax) | At Day 1, 4, 8, 15, 29, 56, 84 and Day 100. | Maximum serum concentration of BI 754132 after a single intravitreal dose (Cmax). Single rising dose (SRD) part. |
| MD Part: Trough Levels of BI 754132 Before Third Administration (Cmin,2) | Up to 57 days. | Systematic exposure of BI 754132 after multiple intravitreal doses as assessed by Cmin,2 (trough levels of BI 754132 before third administration). Multiple dose (MD) part. |
| MD Part: Plasma Concentration of BI 754132 4, 8 and 14 Weeks After the Third Administration | At Day 85, 113 and Day 155. | Plasma concentration of BI 754132 4, 8 and 14 weeks after the third administration. Multiple dose (MD) part. |
| MD Part: Trough Levels of BI 754132 Before Second Administration (Cmin,1) | Up to 29 days. | Systematic exposure of BI 754132 after multiple intravitreal doses as assessed by Cmin,1 (trough levels of BI 754132 before second administration). Multiple dose (MD) part. |
| SRD Part: Number of Patients With Drug-related Adverse Events (AEs) | From drug administration until end of trial, up to 100 days. | Number of patients with drug-related AEs. Single rising dose (SRD) part. |
Countries
United Kingdom, United States
Participant flow
Recruitment details
Open label, non-randomized, uncontrolled trial to test how single rising intravitreal doses and multiple doses of BI 754132 are tolerated in patients with geographic atrophy. Recruitment was to be done successively for the dose groups. The multiple dose (MD) part recruited patients only after the single rising dose (SRD) part was completed and safety of the selected dose was endorsed by the safety monitoring committee.
Pre-assignment details
All subjects were screened for eligibility prior to participation in the trial. Subjects attended a specialist site which ensured that they (the subjects) strictly met all inclusion and none of the exclusion criteria. Subjects were not to be allocated to a treatment group if any of the entry criteria were violated.
Participants by arm
| Arm | Count |
|---|---|
| 0.3 mg BI 754132 - SRD Part 0.3 milligram (mg) BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. Single rising dose (SRD) part. | 3 |
| 1 mg BI 754132 - SRD Part 1 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. SRD part. | 3 |
| 3 mg BI 754132 - SRD Part 3 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. SRD part. | 3 |
| 6 mg BI 754132 - SRD Part 6 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as one single injection on Day 1. One patient was dosed first, and when the safety assessments through Day 4 showed no ophthalmological dose limiting events (DLEs) or systemic DLEs, the remaining patients were dosed. SRD part. | 6 |
| 6 mg BI 754132 - MD Part 6 mg BI 754132 powder for solution for injection 60mg/vial with solution of diluent was administered intravitreally as 3 injections, each separated by 4 weeks (that is, Day 1, Day 29 and Day 57). Multiple dose (MD) part. | 3 |
| Total | 18 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Sponsor put on hold on treatment plan. | 0 | 0 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | 0.3 mg BI 754132 - SRD Part | 1 mg BI 754132 - SRD Part | 3 mg BI 754132 - SRD Part | 6 mg BI 754132 - SRD Part | 6 mg BI 754132 - MD Part | Total |
|---|---|---|---|---|---|---|
| Age, Continuous | 78.3 Years STANDARD_DEVIATION 4.9 | 78.7 Years STANDARD_DEVIATION 2.5 | 70.7 Years STANDARD_DEVIATION 8.1 | 77.7 Years STANDARD_DEVIATION 6 | 77.3 Years STANDARD_DEVIATION 8.3 | 76.7 Years STANDARD_DEVIATION 6.2 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 3 Participants | 3 Participants | 6 Participants | 3 Participants | 18 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 3 Participants | 3 Participants | 3 Participants | 6 Participants | 3 Participants | 18 Participants |
| Sex: Female, Male Female | 2 Participants | 1 Participants | 2 Participants | 5 Participants | 2 Participants | 12 Participants |
| Sex: Female, Male Male | 1 Participants | 2 Participants | 1 Participants | 1 Participants | 1 Participants | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 3 | 0 / 3 | 0 / 6 | 0 / 3 |
| other Total, other adverse events | 1 / 3 | 1 / 3 | 3 / 3 | 3 / 6 | 2 / 3 |
| serious Total, serious adverse events | 1 / 3 | 0 / 3 | 0 / 3 | 1 / 6 | 2 / 3 |
Outcome results
Primary
MD Part: Number of Patients With Drug Related Adverse Events (AEs)
Number of patients with drug-related adverse events (AEs). Multiple dose (MD) part.
Time frame: From drug administration until end of trial, up to 155 days
Population: Treated Set (TS): The TS consisted of all patients who were treated with at least 1 dose of BI 754132. Only participants included in the MD part.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 0.3 mg BI 754132 - SRD Part | MD Part: Number of Patients With Drug Related Adverse Events (AEs) | 2 Participants |
Primary
SRD Part: Number of Patients With Ocular (in the Study Eye) or Systemic Dose Limiting Events (DLEs)
SRD part: Number of patients with ocular or systemic DLEs from drug administration. Systemic DLEs were defined as drug-related adverse events (AEs), as defined by the investigator, of moderate or severe intensity on the Common terminology criteria for adverse events (CTCAE) scale, and included diarrhea, cough, or patient-reported paraesthesia, dysgeusia, taste abnormality, taste disorder, or hyposmia. Single rising dose (SRD) part.
Time frame: From drug administration until end of trial, up to 100 days.
Population: Treated Set (TS): The TS consisted of all patients who were treated with at least 1 dose of BI 754132. Only participants included in the SRD part.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 0.3 mg BI 754132 - SRD Part | SRD Part: Number of Patients With Ocular (in the Study Eye) or Systemic Dose Limiting Events (DLEs) | 0 Participants |
| 1 mg BI 754132 - SRD Part | SRD Part: Number of Patients With Ocular (in the Study Eye) or Systemic Dose Limiting Events (DLEs) | 0 Participants |
| 3 mg BI 754132 - SRD Part | SRD Part: Number of Patients With Ocular (in the Study Eye) or Systemic Dose Limiting Events (DLEs) | 0 Participants |
| 6 mg BI 754132 - SRD Part | SRD Part: Number of Patients With Ocular (in the Study Eye) or Systemic Dose Limiting Events (DLEs) | 0 Participants |
Secondary
MD Part: Plasma Concentration of BI 754132 4, 8 and 14 Weeks After the Third Administration
Plasma concentration of BI 754132 4, 8 and 14 weeks after the third administration. Multiple dose (MD) part.
Time frame: At Day 85, 113 and Day 155.
Population: Pharmacokinetic (PK) parameter analysis set (PKS): The PKS included all patients in the treated set (TS) who provided at least 1 plasma sample for determination of PK parameters and whose data were not excluded due to a protocol violation relevant to the evaluation of the PK or due to PK non-evaluability. Only MD part.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 0.3 mg BI 754132 - SRD Part | MD Part: Plasma Concentration of BI 754132 4, 8 and 14 Weeks After the Third Administration | 4 weeks after the third administration | NA Nanogram/milliliter (ng/mL) |
| 0.3 mg BI 754132 - SRD Part | MD Part: Plasma Concentration of BI 754132 4, 8 and 14 Weeks After the Third Administration | 8 weeks after the third administration | NA Nanogram/milliliter (ng/mL) |
| 0.3 mg BI 754132 - SRD Part | MD Part: Plasma Concentration of BI 754132 4, 8 and 14 Weeks After the Third Administration | 14 weeks after the third administration | NA Nanogram/milliliter (ng/mL) |
Secondary
MD Part: Trough Levels of BI 754132 Before Second Administration (Cmin,1)
Systematic exposure of BI 754132 after multiple intravitreal doses as assessed by Cmin,1 (trough levels of BI 754132 before second administration). Multiple dose (MD) part.
Time frame: Up to 29 days.
Population: Pharmacokinetic (PK) parameter analysis set (PKS): The PKS included all patients in the treated set (TS) who provided at least 1 plasma sample for determination of PK parameters and whose data were not excluded due to a protocol violation relevant to the evaluation of the PK or due to PK non-evaluability. Only MD part.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 0.3 mg BI 754132 - SRD Part | MD Part: Trough Levels of BI 754132 Before Second Administration (Cmin,1) | NA Nanogram/milliliter (ng/mL) |
Secondary
MD Part: Trough Levels of BI 754132 Before Third Administration (Cmin,2)
Systematic exposure of BI 754132 after multiple intravitreal doses as assessed by Cmin,2 (trough levels of BI 754132 before third administration). Multiple dose (MD) part.
Time frame: Up to 57 days.
Population: Pharmacokinetic (PK) parameter analysis set (PKS): The PKS included all patients in the treated set (TS) who provided at least 1 plasma sample for determination of PK parameters and whose data were not excluded due to a protocol violation relevant to the evaluation of the PK or due to PK non-evaluability. Only MD part.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 0.3 mg BI 754132 - SRD Part | MD Part: Trough Levels of BI 754132 Before Third Administration (Cmin,2) | NA Nanogram/milliliter (ng/mL) |
Secondary
SRD Part: Area Under the Concentration-time Curve of BI 754132 in Serum Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Area under the concentration-time curve of BI 754132 in serum over the time interval from 0 extrapolated to infinity (AUC0-∞). Singe rising dose (SRD) part.
Time frame: At Day 1, 4, 8, 15, 29, 56, 84 and Day 100.
Population: Pharmacokinetic (PK) parameter analysis set (PKS): The PKS included all patients in the treated set (TS) who provided at least 1 plasma sample for determination of PK parameters and whose data were not excluded due to a protocol violation relevant to the evaluation of the PK or due to PK non-evaluability. Only SRD part. For the 6 mg arm: Only patients with measurable serum concentration of BI (2 out of 6) are reported.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 0.3 mg BI 754132 - SRD Part | SRD Part: Area Under the Concentration-time Curve of BI 754132 in Serum Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | NA Hours*nanogram per milliliter (h*ng/mL) | — |
| 1 mg BI 754132 - SRD Part | SRD Part: Area Under the Concentration-time Curve of BI 754132 in Serum Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | NA Hours*nanogram per milliliter (h*ng/mL) | — |
| 3 mg BI 754132 - SRD Part | SRD Part: Area Under the Concentration-time Curve of BI 754132 in Serum Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | NA Hours*nanogram per milliliter (h*ng/mL) | — |
| 6 mg BI 754132 - SRD Part | SRD Part: Area Under the Concentration-time Curve of BI 754132 in Serum Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | 4620 Hours*nanogram per milliliter (h*ng/mL) | Standard Deviation 2220 |
Secondary
SRD Part: Maximum Serum Concentration of BI 754132 After a Single Intravitreal Dose (Cmax)
Maximum serum concentration of BI 754132 after a single intravitreal dose (Cmax). Single rising dose (SRD) part.
Time frame: At Day 1, 4, 8, 15, 29, 56, 84 and Day 100.
Population: Pharmacokinetic (PK) parameter analysis set (PKS): The PKS included all patients in the treated set (TS) who provided at least 1 plasma sample for determination of PK parameters and whose data were not excluded due to a protocol violation relevant to the evaluation of the PK or due to PK non-evaluability. Only SRD part. For the 6 mg arm: Only patients with measurable serum concentration of BI (2 out of 6) are reported.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 0.3 mg BI 754132 - SRD Part | SRD Part: Maximum Serum Concentration of BI 754132 After a Single Intravitreal Dose (Cmax) | NA nanogram/milliliter (ng/mL) | — |
| 1 mg BI 754132 - SRD Part | SRD Part: Maximum Serum Concentration of BI 754132 After a Single Intravitreal Dose (Cmax) | NA nanogram/milliliter (ng/mL) | — |
| 3 mg BI 754132 - SRD Part | SRD Part: Maximum Serum Concentration of BI 754132 After a Single Intravitreal Dose (Cmax) | NA nanogram/milliliter (ng/mL) | — |
| 6 mg BI 754132 - SRD Part | SRD Part: Maximum Serum Concentration of BI 754132 After a Single Intravitreal Dose (Cmax) | 26.9 nanogram/milliliter (ng/mL) | Standard Deviation 2.55 |
Secondary
SRD Part: Number of Patients With Any Ocular Adverse Events (AEs) in the Study Eye
Number of patients with any ocular adverse events in the study eye. Single rising dose (SRD) part.
Time frame: From drug administration until end of trial, up to 100 days.
Population: Treated Set (TS): The TS consisted of all patients who were treated with at least 1 dose of BI 754132. Only participants included in the SRD part.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 0.3 mg BI 754132 - SRD Part | SRD Part: Number of Patients With Any Ocular Adverse Events (AEs) in the Study Eye | 1 Participants |
| 1 mg BI 754132 - SRD Part | SRD Part: Number of Patients With Any Ocular Adverse Events (AEs) in the Study Eye | 1 Participants |
| 3 mg BI 754132 - SRD Part | SRD Part: Number of Patients With Any Ocular Adverse Events (AEs) in the Study Eye | 2 Participants |
| 6 mg BI 754132 - SRD Part | SRD Part: Number of Patients With Any Ocular Adverse Events (AEs) in the Study Eye | 2 Participants |
Secondary
SRD Part: Number of Patients With Drug-related Adverse Events (AEs)
Number of patients with drug-related AEs. Single rising dose (SRD) part.
Time frame: From drug administration until end of trial, up to 100 days.
Population: Treated Set (TS): The TS consisted of all patients who were treated with at least 1 dose of BI 754132. Only participants included in the SRD part.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 0.3 mg BI 754132 - SRD Part | SRD Part: Number of Patients With Drug-related Adverse Events (AEs) | 1 Participants |
| 1 mg BI 754132 - SRD Part | SRD Part: Number of Patients With Drug-related Adverse Events (AEs) | 0 Participants |
| 3 mg BI 754132 - SRD Part | SRD Part: Number of Patients With Drug-related Adverse Events (AEs) | 1 Participants |
| 6 mg BI 754132 - SRD Part | SRD Part: Number of Patients With Drug-related Adverse Events (AEs) | 1 Participants |
Secondary
SRD Part: Time From Dosing to Maximum Serum Concentration of BI 754132 (Tmax)
Time from dosing to maximum serum concentration of BI 754132 (tmax). Single rising dose (SRD part).
Time frame: At Day 1, 4, 8, 15, 29, 56, 84 and Day 100.
Population: Pharmacokinetic (PK) parameter analysis set (PKS): The PKS included all patients in the treated set (TS) who provided at least 1 plasma sample for determination of PK parameters and whose data were not excluded due to a protocol violation relevant to the evaluation of the PK or due to PK non-evaluability. Only SRD part. For the 6 mg arm: Only patients with measurable serum concentration of BI (2 out of 6) are reported.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 0.3 mg BI 754132 - SRD Part | SRD Part: Time From Dosing to Maximum Serum Concentration of BI 754132 (Tmax) | NA Hours (h) | — |
| 1 mg BI 754132 - SRD Part | SRD Part: Time From Dosing to Maximum Serum Concentration of BI 754132 (Tmax) | NA Hours (h) | — |
| 3 mg BI 754132 - SRD Part | SRD Part: Time From Dosing to Maximum Serum Concentration of BI 754132 (Tmax) | NA Hours (h) | — |
| 6 mg BI 754132 - SRD Part | SRD Part: Time From Dosing to Maximum Serum Concentration of BI 754132 (Tmax) | 72.5 Hours (h) | Standard Deviation 96.9 |